Download full report with analyst certification and important disclosures
Sep 3 2019, 07:10 IST/BST
Malin Corporation
H1 2019 results: value/price disconnect compelling
- Sectors : Pharma and healthcare
- Companies : Malin Corporation
DAVY VIEW
The modest 5% reduction in Malin’s IPEV stands in stark contrast to its 52% share price decline year-to-date. The latter is largely driven by overhang concerns due to Woodford IM’s 23% stake. With several significant valuation milestones approaching in 2019 and 2020, and the scope for capital returns, Malin’s share price discount of almost 70% to its IPEV-derived fair value per share of €7.9 provides a compelling opportunity for investors to generate outsized returns over the next 18 months.
